Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 2/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462269 | 0.90 | RIPK1 (0.36) | TACR1SLC6A3SLC6A4 | |
| SCHEMBL4459909 | 0.85 | TACR1 (0.34) | TACR1SLC6A3SLC6A4RBP4UBE2M | |
| SCHEMBL20336686 | 0.78 | PRCP (0.33) | SLC6A3SLC6A4PRCP | |
| SCHEMBL21874133 | 0.74 | FKBP1A (0.31) | — | |
| SCHEMBL4462143 | 0.74 | RIPK1 (0.36) | TACR1 | |
| SCHEMBL15951884 | 0.74 | RIPK1 (0.36) | — | |
| SCHEMBL4114777 | 0.74 | ALDH1A1 (0.37) | TACR1SLC6A3SLC6A4ALDH1A1TACR3 | |
| SCHEMBL3993930 | 0.74 | ALDH1A1 (0.37) | TACR1SLC6A3SLC6A4ALDH1A1TACR3 | |
| SCHEMBL3987952 | 0.74 | ALDH1A1 (0.37) | TACR1SLC6A3SLC6A4ALDH1A1TACR3 | |
| SCHEMBL4456493 | 0.73 | TACR1 (0.46) | TACR1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | TACR1, PROKR1, TACR2 | TACR1 1/4885SLC6A3 500/4885SLC6A4 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.